Author: Ken Dropiewski

Novo Nordisk Foundation grants DKK 25 million ($3.3 million) for completion of clinical trial to improve treatment outcomes for people with critical limb ischaemia

COPENHAGEN, Denmark, Nov. 2, 2022 /PRNewswire/ — The grant will enable leading international researchers to complete a clinical trial comparing the two most common treatment methods for preventing leg amputation among people with critical limb ischaemia. Critical limb ischaemia is a serious and debilitating disease that affects about 22 million people globally, […]

Shanghai Operation Robot announced the first Robot-assisted human clinical trial of biliary stent placement surgery

SHANGHAI, Nov. 2, 2022 /PRNewswire/ — Shanghai Operation Robot Co.,Ltd announced the results of its initial clinical trial of ERCP (Endoscopic retrograde cholangiopancreatography) robot in biliary stent placement surgery. It is the first Robot-assisted human clinical trial of biliary stent placement surgery in the world. The surgery was conducted by Aopeng Medical. The […]

ViewRay Announces Third Quarter 2022 Results

DENVER, Nov. 1, 2022 /PRNewswire/ — ViewRay, Inc. (Nasdaq: VRAY) (the “Company”) today announced financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Highlights Total revenue for the third quarter 2022 was approximately $26.5 million, primarily from four revenue units, compared to approximately $19.2 million, primarily from three revenue units, in the third […]

Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CARLSBAD, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on November 1, 2022 that were approved by the Compensation Committee of its Board of […]

CVRx Reports Third Quarter 2022 Financial and Operating Results

Third quarter 2022 revenue of $6.2 million, an 82% increase over prior year MINNEAPOLIS, Nov. 01, 2022 (GLOBE NEWSWIRE) — CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for […]

iRhythm Technologies Announces Third Quarter 2022 Financial Results

SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today reported financial results for the three months ended September 30, 2022. Third Quarter 2022 Financial Results Revenue of $103.9 million, a 21.6% […]

LEXEO Therapeutics Bolsters Cardiac Gene Therapy Leadership with New Executive Appointment and Formation of Scientific Advisory Board

Eric Adler, M.D., joins LEXEO as Chief Scientific Officer New Scientific Advisory Board comprised of molecular cardiology, cardiovascular imaging, cardiac gene-editing, and RNA biology experts NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) — LEXEO Therapeutics, Inc. (LEXEO), a clinical-stage biotech company advancing a pipeline of adeno-associated virus (AAV)-based gene therapy candidates […]

Viz.ai Partners with Us2.ai to Deliver AI-Enabled Echocardiography Decision Support with the Viz™ Platform

Partnership delivers critical insights to cardiac care teams for faster patient triage and care SAN FRANCISCO–(BUSINESS WIRE)–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has partnered with Us2.ai, the developer of AI software that fully automates a complete echocardiography, or heart ultrasound, report. Under the […]

24-Month Data from Surmodics’ TRANSCEND Trial Presented at VIVA 2022 Conference

SurVeil™ Drug Coated Balloon (DCB) demonstrates sustained durability of safety, efficacy endpoints SurVeil™ DCB non-inferior to market leading IN.PACT® Admiral® DCB at a substantially lower drug dose EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 24-month […]